| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2019-2022 |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Colorectal Cancer (CRC) Market Size 2024 |
USD 21.6 billion |
| Colorectal Cancer (CRC) Market, CAGR |
4.07% |
| Colorectal Cancer (CRC) Market Size 2032 |
USD 15.7 billion |
Market Overview:
The global colorectal cancer (CRC) market is projected to experience steady growth, reaching an estimated USD 21.6 billion by 2032 from USD 15.7 billion in 2024, reflecting a Compound Annual Growth Rate (CAGR) of 4.07%.
The rising prevalence of colorectal cancer globally, attributed to factors such as population aging and lifestyle changes, underscores the need for effective interventions and treatments. Early detection initiatives, bolstered by advancements in diagnostic tools like colonoscopies and DNA tests, are pivotal in improving patient outcomes by enabling timely interventions. Moreover, the expanding landscape of treatment options, including targeted therapies and immunotherapies, offers personalized approaches tailored to individual patients’ needs and disease characteristics. Alongside these developments, technological advancements such as minimally invasive surgical techniques and robotics-assisted surgery are enhancing treatment efficacy and patient experience, driving the evolution of colorectal cancer management.
In the competitive landscape, established pharmaceutical giants like F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Eli Lilly and Company are leading the charge with innovative therapies and strategic expansions. However, the market’s dynamism is further fueled by the contributions of regional and emerging players, who bring fresh perspectives and innovations through research collaborations and strategic partnerships. Geographically, while North America currently dominates the market due to its robust healthcare infrastructure and early adoption of advanced technologies, Asia Pacific is poised for rapid growth. Factors such as a burgeoning geriatric population, increasing awareness, and escalating healthcare investments are expected to drive significant market expansion in the region. Europe and the Rest of the World are also anticipated to witness steady growth, propelled by ongoing research efforts and advancements in treatment modalities.
Access crucial information at unmatched prices!
Request your free sample report today & start making informed decisions powered by Credence Research!
Download Free Sample
Market Drivers:
Rising Prevalence of Colorectal Cancer:
A significant driver is the increasing global incidence of colorectal cancer. For instance, colorectal cancer is the third most common cancer worldwide, accounting for approximately 10% of all cancer cases. In 2020, more than 1.9 million new cases of colorectal cancer and more than 930,000 deaths due to colorectal cancer were estimated to have occurred worldwide. This growth is attributed to various factors, including aging populations, lifestyle changes like unhealthy diets and physical inactivity, and rising obesity rates. For example, the prevalence of obesity in the older population has been on the rise, with 37.1% of men and 33.6% of women aged 60 years and older classified as having obesity. As the population ages and risk factors become more prevalent, the demand for diagnostic tools, treatment options, and post-surgical care is expected to rise correspondingly.
Growing Awareness and Early Detection:
Increased public awareness campaigns and improved screening programs are leading to earlier detection of colorectal cancer. Regular screenings are crucial for early detection of colorectal cancer. However, only about 4 out of 10 colorectal cancers are found at this early stage. The use of diagnostic tools like colonoscopies and fecal occult blood tests is increasing. For instance, more than 80% of people with a positive fecal occult blood test result have a follow-up colonoscopy recorded within 360 days. Early detection allows for more effective treatment options and improves patient outcomes. This rise in early detection translates to a growing need for diagnostic tools like colonoscopies and fecal occult blood tests, propelling the market forward.
Technological Advancements in Treatment Options:
The field of colorectal cancer treatment is witnessing continuous advancements. For instance, new and improved surgical techniques, targeted therapies, and immunotherapies are offering better treatment outcomes and potentially reducing treatment side effects. The death rate from colorectal cancer has dropped by 55% in men since 1980 and 60% in women since 1969, largely attributed to these advancements in treatment and increased screening. The development and adoption of these advanced therapies are creating new market opportunities for pharmaceutical and medical device companies.
Expanding Healthcare Infrastructure in Emerging Markets:
Developing economies are experiencing significant growth in their healthcare infrastructure. This includes the establishment of new hospitals, specialized cancer care centers, and increased access to diagnostic and treatment technologies. This improved healthcare infrastructure in emerging markets is creating a larger potential patient base and driving demand for colorectal cancer treatment solutions.
Market Trends:
Rising Incidence Rates and Aging Population:
Colorectal cancer is the third most common cancer worldwide, accounting for approximately 10% of all cancer cases. For instance, in 2020, more than 1.9 million new cases of colorectal cancer and more than 930,000 deaths due to colorectal cancer were estimated to have occurred worldwide. This cancer predominantly affects older individuals, with the majority of cases occurring in people aged 50 and above. This growing patient pool will fuel demand for diagnostic tools, treatment options, and supportive care products. Early detection through regular screenings remains crucial in improving patient outcomes.
Advancements in Treatment Options:
The field of colorectal cancer treatment has seen significant advancements. For instance, the use of immunotherapy drugs such as ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda) has shown promise. These drugs are used to help shrink and control the growth of metastatic colorectal cancer which has a high microsatellite instability.In terms of surgical advancements, minimally invasive procedures like endoscopic surgery and transanal minimally invasive surgery (TAMIS) are being used to treat early-stage colorectal cancer. These techniques can lead to faster recovery times and less post-surgical pain. For instance, a study found that patients who underwent minimally invasive surgery had a median hospital stay of 5 days compared to 8 days for those who underwent open surgery.Personalized medicine is another area of advancement, allowing for tailoring treatment plans to individual patient characteristics and mutations, potentially leading to more effective therapies. For instance, a study found that patients with a certain mutation (KRAS mutation) did not respond well to a certain type of therapy (EGFR inhibitors), leading to the development of more targeted therapies.
Market Challenges Analysis:
Addressing Limited Early Detection:
Colorectal cancer’s silent progression in its early stages underscores the urgency of enhancing early detection efforts. Public awareness campaigns play a pivotal role in educating individuals about risk factors, symptoms, and the importance of regular screenings. Moreover, expanding access to screening programs, particularly colonoscopies and other effective methods, is essential, especially for underserved communities. The development of innovative, non-invasive screening tools aims to improve patient compliance and enhance early detection rates, thereby mitigating the challenges associated with delayed diagnoses and improving prognoses.
Navigating Rising Treatment Costs:
While novel therapies for colorectal cancer offer improved patient outcomes, they often come with significant costs, posing challenges to accessibility and affordability. To address this, collaboration between pharmaceutical companies, healthcare providers, and policymakers is imperative to develop sustainable pricing models for new treatments. Exploring value-based pricing strategies that link drug costs to treatment outcomes can incentivize cost-effectiveness while ensuring equitable access. Additionally, supporting research into generic versions of colorectal cancer drugs can contribute to long-term affordability, enhancing accessibility to life-saving treatments for all patients.
Segmentation Analysis:
By Treatment:
Colorectal cancer treatment encompasses various modalities tailored to the patient’s condition and disease stage. Chemotherapy, a cornerstone therapy, utilizes potent drugs to eradicate cancer cells, often in combination with other treatments. Targeted therapy offers a more personalized approach by targeting specific molecules involved in cancer growth, potentially minimizing side effects. Radiation therapy employs high-energy rays to shrink tumors or eliminate cancer cells, while surgery remains fundamental for tumor removal, varying in invasiveness depending on cancer stage and location. Immunotherapy, an emerging approach, harnesses the body’s immune system to combat cancer cells, showing promise for advanced cases. Additionally, minimally invasive techniques like embolization and emerging therapies such as gene therapy and cryotherapy offer innovative avenues for treatment, though their applications may be limited or under development.
By Administration Route:
The route of administration significantly influences treatment convenience and patient adherence. Oral administration provides a convenient option for certain chemotherapy and targeted therapy medications, enhancing patient comfort and compliance. Parenteral administration, including intravenous injections and infusions, is commonly used for delivering chemotherapy, targeted therapies, and supportive medications. Other administration routes, such as topical applications and potential advancements in drug delivery methods, present areas for future exploration in optimizing treatment efficacy and patient experience.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Segments:
Based on Treatment:
- Chemotherapy
- Targeted Therapy
- Radiation Therapy
- Surgery
- Immunotherapy
- Embolization
- Others
Based on Route of Administration:
Based on End User:
- Hospitals
- Homecare
- Specialty Clinics
- Others
Based on Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Based on Regional:
North America
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
Latin America
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Regional Analysis:
North America
The North America region commands the largest market share, estimated at around 40-45%. This dominant position can be attributed to factors such as advanced healthcare infrastructure, high awareness about colorectal cancer screening, and the presence of major pharmaceutical and biotechnology companies in the region. The United States and Canada are the key contributors to this market.
Europe
Europe holds a significant market share of approximately 25-30%. This region benefits from well-established healthcare systems, government initiatives for cancer awareness and prevention, and a strong focus on research and development activities in the field of colorectal cancer. Major markets within Europe include Germany, France, the United Kingdom, and Italy.
Key player:
- Genentech, Inc.
- Eli Lilly and Company
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Bristol Myers Squibb
- Sanofi
- Merck Sharp & Dohme Corp.
- Taiho Pharmaceutical (Otsuka Pharmaceutical Co., Ltd.)
- Bayer AG
- Regeneron Pharmaceuticals, Inc.
- Novartis AG
- Ipsen Biopharmaceuticals, Inc.
Competitive Analysis:
Several key players contribute to the landscape of colorectal cancer treatment. F. Hoffmann-La Roche Ltd. maintains a robust position with established drugs such as Avastin and Erbitux, integral to various treatment regimens. Merck & Co., Inc. offers respected therapies like Keytruda, steadily expanding its presence and influencing treatment standards. Eli Lilly and Company, known for prominent drugs like Erbitux, commands a significant market share in colorectal cancer treatment. Bristol-Myers Squibb Company provides established treatments like Opdivo and actively invests in developing new therapies to address unmet needs. Pfizer Inc. sustains a market presence with drugs like Xeloda while continuously exploring new treatment options, potentially broadening its portfolio.
Recent Developments:
In May 2022, Bruker launched an innovative 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets for its market-leading preclinical magnetic resonance imaging (MRI) systems portfolio. Following the success of its BioSpec Maxwell 3 Tesla model, the new range of Maxwell 7 Tesla and 9.4 Tesla magnets eliminates the need for liquid Helium or Nitrogen refills while offering high-field sensitivity and resolution for advanced preclinical MRI and PET/MR research.
In April 2022, the United States Food and Drug Administration approved the third biosimilar for the monoclonal antibody bevacizumab-bevacizumab-maly (Amsys)-for the treatment of subsets of patients with colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer.
In March 2022, Chugai Pharmaceutical Co., Ltd. obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for the anti-HER2 humanized monoclonal antibodies, Perjeta for intravenous infusion, and Herceptin for intravenous infusion, for the additional indication of advanced or recurrent HER2-positive colon cancer or rectal cancer not amenable to curative resection that has progressed after cancer chemotherapy.
In January 2022, Amgen and Generate Biomedicines entered a research collaboration agreement to discover and develop protein therapeutics for five clinical targets across multiple therapeutic areas and modalities. The collaboration will increase drug discovery efforts, generating novel protein sequences with optimal therapeutic properties.
Market Concentration & Characteristics:
The colorectal cancer market exhibits a moderately concentrated competitive landscape. While a few major pharmaceutical and biotechnology companies hold a significant share with established treatment options, there is a growing presence of emerging players. These new entrants are developing novel therapies, particularly in the areas of targeted therapies and immunotherapies. This trend indicates a shift towards a more diversified market in the coming years, with increased competition and potentially more innovative treatment options for colorectal cancer patients.
Report Coverage:
The research report offers an in-depth analysis based on Treatment, Route of Administration, End Use, Distribution Channel and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook:
- Increased awareness campaigns and adoption of non-invasive screening methods like stool DNA tests are likely to lead to earlier diagnoses, potentially improving treatment outcomes and reducing overall healthcare costs.
- Development of targeted therapies based on specific genetic mutations and tumor profiles will enable more precise treatment approaches, potentially leading to improved efficacy and reduced side effects.
- Continued advancements in laparoscopic and robotic surgery will offer patients less invasive treatment options, resulting in faster recovery times and improved quality of life.
- The growing understanding of the immune system’s role in cancer is leading to the development of novel immunotherapies, offering promising prospects for long-term disease control and potential cures.
- AI is poised to play a significant role in colorectal cancer diagnosis, treatment planning, and drug discovery. AI-powered tools can analyze complex datasets, personalize treatment approaches, and accelerate the development of new therapies.
- The increasing use of telehealth services for consultations, monitoring, and post-operative care can improve access to care, particularly in remote areas, and enhance patient convenience.
- Healthcare systems are shifting towards value-based care models, emphasizing treatment effectiveness and cost-efficiency. This can lead to increased focus on preventive measures, early detection, and cost-effective treatment options for colorectal cancer.
- Rising disposable income and growing awareness of colorectal cancer in developing countries are expected to drive market growth for diagnostic tools and treatment solutions in these regions.
- Strategic collaborations between established pharmaceutical companies and innovative biotech firms can accelerate research and development efforts, leading to a faster pipeline of novel therapeutic options for colorectal cancer patients.
- Growing recognition of the importance of patient support throughout the treatment journey and during recovery is likely to lead to increased investment in patient support programs and rehabilitation services, improving overall patient well-being.
